Translate Bio Inc. Common Stock
(NASDAQ:TBIO)
Description
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
TBIO Overview
None
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$1.3200 |
Previous Close Volume |
118920 |